What Modafinil Teva Treats: Main Uses and Benefits

The medication is commonly applied to address the chronic and debilitating Excessive Daytime Sleepiness (EDS) associated with specific medical conditions, including Narcolepsy, Obstructive Sleep Apnea (OSA), and Shift Work Sleep Disorder (SWSD). It is applicable across domains where additional symptomatic support is needed, primarily to manage symptoms related to systemic imbalance.

“It provides support that helps ease the overall symptom load and assists patients with coping more steadily with difficult episodes of somnolence.”

This medicine is commonly used to help with symptoms that are a core feature of primary neurological conditions, supporting sustained alertness and vigilance during scheduled waking hours. It is also relevant for managing sleepiness that arises in specific clinical contexts, such as the disruption of the circadian rhythm in shift work or residual daytime sleepiness in OSA patients optimized on primary treatments, assisting with maintaining functional stability when symptoms become more noticeable.

Quick Fact	Symptom Support for Excessive Daytime Sleepiness (EDS)

Regulatory References

1. NIH MedlinePlus overview

Eligibility Map: Who can and cannot use Modafinil Teva — Official Regulatory Information

The eligibility profile for Modafinil Teva is based strictly on governmental regulatory documents and defines which populations are approved for use and which are explicitly restricted or contraindicated.

Eligibility Scope

Category	Official Regulatory Status
Populations for Standard Use	Adult patients (aged 18 and over) diagnosed with excessive daytime sleepiness associated with Narcolepsy, Obstructive Sleep Apnea (OSA), or Shift Work Disorder (SWD).
Populations for whom use is Contraindicated	Patients with known hypersensitivity to modafinil or armodafinil. Individuals with uncontrolled moderate to severe hypertension, cardiac arrhythmias, left ventricular hypertrophy, or cor pulmonale. Women who are pregnant (due to suspected teratogenicity risk).
Age-related Eligibility Rules	Pediatric use (under 18 years) is generally not recommended or safety and effectiveness are not established. Geriatric patients (ge 65 years) require a lower starting dose due to potential for reduced clearance.
Condition-specific Eligibility Rules	Patients with severe hepatic impairment (liver failure) require the dosage to be reduced by half. Use in patients with severe renal impairment requires caution.
Pregnancy and Lactation Status	Contraindicated in pregnancy. Women of childbearing potential must use effective non-hormonal contraception during treatment and for two months after discontinuation. Use is not recommended while breastfeeding.

Connection to the overall eligibility profile

Official documents restrict this medicine to adults who meet specific criteria for sleep disorders. Use is prohibited by absolute contraindications related to cardiac health and hypersensitivity. Eligibility is conditional upon organ function and a mandatory contraception protocol for women of reproductive potential, reflecting specific safety and population-based limitations.

The interaction profile of Modafinil Teva is primarily defined by its effects on liver enzymes responsible for drug metabolism. The medicine is classified as a moderate inducer of CYP3A4/5 and a reversible inhibitor of CYP2C19, which results in two distinct pharmacokinetic interaction patterns.

Interaction Type	Affected Medicine Examples	Interaction Outcome (Regulatory Description)
Enzyme Induction (CYP3A4/5)	Steroidal Contraceptives, Ciclosporin, Triazolam	Reduces the systemic exposure and efficacy of the co-administered medicine.
Enzyme Inhibition (CYP2C19)	Diazepam, Phenytoin, Omeprazole	Decreases the clearance of the co-administered medicine, potentially increasing its plasma concentration.

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally classified by regulatory authorities as a contraindicated combination. Due to the induction of CYP3A4/5, the use of steroidal contraceptives (e.g., oral, patch, ring) is associated with a risk of diminished effectiveness. For this reason, regulatory documents require the use of alternative, non-hormonal contraception during treatment and mandate that this alternative method be continued for two months following the discontinuation of Modafinil Teva. Food intake may delay the time required to reach maximal absorption by approximately one hour but does not alter the total amount of medicine absorbed. Clearance of the medicine may be reduced in patients with severe hepatic impairment.

How Modafinil Teva Works

The mechanism of Modafinil is defined by its selective influence on key neurotransmitter systems associated with arousal, demonstrating a unique pharmacological profile compared to traditional psychostimulants.

Atypical Dopamine Reuptake Inhibition

The molecule's primary action is to bind to the Dopamine Transporter (DAT) on nerve endings. This inhibition reduces the reabsorption of dopamine back into the neuron, resulting in elevated extracellular dopamine concentrations in specific brain regions. This initial molecular step acts as the trigger for the drug's downstream effects, distinguishing its pharmacological profile from mechanisms of non-selective monoamine releasers.

Indirect Activation of Orexin-Histamine Pathways

The increase in dopamine initiates a key, indirect cascade involving the hypothalamus. The mechanism selectively enhances the activity of neurons that produce Orexin (Hypocretin), neuropeptides associated with the maintenance of arousal. The activation of the Orexin system subsequently drives the release of Histamine from specialized neurons. This engagement of the Orexin and Histamine pathways is central to modulating overall cortical arousal and supporting the maintenance of consciousness.

Modulation of Excitatory/Inhibitory Balance

Modafinil also modulates the balance between activating and calming signals in the brain. The mechanism enhances glutamatergic (excitatory) signaling while attenuating local GABAergic (inhibitory) input in key regulatory nuclei. This shift influences the activity of inhibitory signals, contributing to the physiological outcome of sustained arousal.

Dosing and Administration Overview

Modafinil Teva is a medication intended for oral administration and is available in tablet strengths of 100 mg and 200 mg, which must be swallowed whole. The standard dose is 200 mg daily; although doses up to 400 mg/day have been used, there is no consistent evidence of additional clinical benefit above the 200 mg dose.

Standard Dosing Schedules

The timing of the daily dose is conditional on the diagnosed sleep disorder:

• Narcolepsy and Obstructive Sleep Apnea (OSA): The standard dose is 200 mg taken once a day in the morning. The total daily dose may be taken as a single dose or divided into two doses (morning and noon).
• Shift Work Sleep Disorder (SWSD): The recommended dose is 200 mg taken once a day approximately one hour prior to the start of the work shift.

Practical Use Instructions

The medicine may be taken with or without food. For patients with OSA, the medication is intended as an adjunct to primary treatments (e.g., Continuous Positive Airway Pressure - CPAP), and a maximal effort to treat with the primary therapy should be continued. Treatment is initiated and supervised by a physician with appropriate knowledge of sleep disorders.

Dosing for Specific Populations

Dose adjustments are recommended for certain patient groups:

Population	Dosing Instruction
Severe Hepatic Impairment	Dose should be reduced by half (e.g., maximum 100 mg daily).
Geriatric Patients (>65 yrs)	Use of lower initial doses (e.g., 100 mg daily) and close monitoring is recommended.
Pediatric Patients (<18 yrs)	Not recommended; safety and efficacy have not been established.

Research Evidence / Overview of Studies for Modafinil Teva

Evidence for Use in Narcolepsy

The research into Modafinil Teva for the excessive daytime sleepiness (EDS) associated with narcolepsy is based primarily on short-term, randomized, placebo-controlled clinical trials (RCTs). These studies were conducted using adult populations diagnosed with narcolepsy. Researchers monitored objective outcomes reflecting daily functioning and patient-reported experiences of sleepiness using scales like the Epworth Sleepiness Scale (ESS) and tests like the Maintenance of Wakefulness Test (MWT). Findings describe patterns observed in the studies where measurements of both subjective and objective sleepiness measures were monitored during the short observation periods. This research mainly focuses on EDS and generally does not provide data on core symptoms of narcolepsy like cataplexy.

Evidence for Use in Obstructive Sleep Apnea (OSA)

Research exploring the use of Modafinil Teva for residual excessive daytime sleepiness in patients with Obstructive Sleep Apnea (OSA) has used short-term RCTs and systematic reviews. The populations studied were adults who continued to experience significant sleepiness despite being optimally treated with a primary therapy, such as CPAP. The medicine was evaluated in a research context as an adjunct—meaning it was studied alongside the standard treatment, not as a replacement for it. Although research highlights changes measured during the study period, the evidence is limited, and findings were mixed across some analyses.

Evidence for Use in Shift Work Sleep Disorder (SWSD)

The evidence base for Shift Work Sleep Disorder (SWSD) is also composed of short-term, randomized, placebo-controlled clinical trials. This research examined temporary physiological imbalance in adults whose work schedules disrupt their natural sleep-wake cycle. The research describes patterns where alertness measures were monitored over the short study durations. The evidence derived from these settings is limited, and subgroup findings are uncertain.

Key Areas of Uncertainty and Remaining Research Gaps

The core double-blind clinical trials examining the use of Modafinil Teva typically had follow-up durations that were limited, often lasting only 9 to 12 weeks. Research is ongoing, but there is limited information for long-term outcomes. The full scope of changes in daily functioning over many years is not well characterized. Additionally, the effectiveness in pediatric patients (children and adolescents) has not been determined, and research in these groups is limited. Dedicated research in older adults is also limited.

Key Studies & References Modafinil: MedlinePlus Drug Information

Common questions about Modafinil Teva (FAQ)

Q: What is Modafinil Teva used for?

Modafinil Teva is a medication used to help improve wakefulness in adult patients who experience excessive sleepiness associated with specific conditions, including narcolepsy, obstructive sleep apnea (OSA), and shift work disorder (SWD). For OSA, it is used as an adjunctive treatment to primary therapy, such as CPAP.

---

Q: Is Modafinil Teva a permanent cure for sleep disorders?

Modafinil Teva is intended to manage the symptoms of excessive sleepiness. It is not a replacement for sleep or for maintaining good sleep hygiene. The underlying sleep disorder should continue to be treated. The effectiveness of long-term use has not been systematically evaluated beyond a certain period in clinical trials.

---

Q: What serious side effects have been associated with Modafinil Teva?

Rare but serious side effects have been reported with modafinil use, including serious skin rashes (such as Stevens-Johnson Syndrome, or SJS), multi-organ hypersensitivity reactions, angioedema, and anaphylaxis. Patients should be monitored for the development or worsening of psychiatric symptoms, such as anxiety, psychosis, or suicidal ideation. If a rash or signs of a hypersensitivity reaction appear, the medication should be stopped and a healthcare professional should be contacted immediately.

---

Q: Can Modafinil Teva affect the effectiveness of other medications?

Yes, Modafinil Teva may affect the way other medications work. For example, it may reduce the effectiveness of hormonal contraceptives (including birth control pills). It is important to discuss all concurrent medications and supplements with a healthcare professional before starting treatment.

How to Store and Dispose of Modafinil Teva?

Modafinil tablets must be stored according to official regulatory labeling to maintain stability and prevent misuse. The required storage condition is controlled room temperature, typically between 20 C and 25 C (68 F and 77 F).

Storage Requirements

Requirement	Condition
Temperature	Controlled room temperature (below 25 C).
Protection	Keep from freezing, moisture, and direct light.
Container	Store in the original closed container.
Safety	Keep out of the sight and reach of children and store securely.

Disposal

Unused or expired Modafinil must be disposed of in accordance with local requirements for pharmaceutical waste. Do not dispose of the medication in wastewater. Federal guidelines recommend utilizing drug take-back programs or authorized collectors for proper discarding.